重組抗體
重組抗體，也稱為基因工程抗體，是指通過DNA重組技術(shù)將抗體相應(yīng)的基因序列根據(jù)需要進(jìn)行改造和重組，并構(gòu)建在質(zhì)粒上，再通過蛋白外源表達(dá)技術(shù)將構(gòu)建好的質(zhì)粒轉(zhuǎn)染/轉(zhuǎn)化入適合的宿主細(xì)胞表達(dá)獲得的抗體。換言之，重組抗體是通過將免疫特異性重鏈和輕鏈抗體克隆到高產(chǎn)的哺乳動(dòng)物表達(dá)載體中而制成的。將得到的載體引入到表達(dá)宿主（如細(xì)菌、酵母或哺乳動(dòng)物）中，用于生產(chǎn)高質(zhì)量的功能性抗體。重組抗體很好的解決了動(dòng)物源抗體引起的人體排斥反應(yīng)，使得抗體實(shí)現(xiàn)人源化，使抗體的效能更為完善。
重組抗體可分為五大類：嵌合抗體、人源化抗體、全人源化抗體、小分子抗體、雙特異性抗體。近年來，重組抗體的使用在治療和診斷中變得越來越廣泛。與傳統(tǒng)抗體相比具有顯著優(yōu)勢，卓越的批次間一致性、持續(xù)供應(yīng)和非動(dòng)物源優(yōu)勢使得重組抗體變得越來越受青睞，最重要的一點(diǎn)是重組抗體可以最大化人源化以解決不同物種之間的異質(zhì)性。
華美生物目前已開發(fā)1000多種重組抗體，具有高純度、親和力強(qiáng)以及批次間偏差小等特點(diǎn)，涉及癌癥、心血管疾病、細(xì)胞生物學(xué)、免疫學(xué)、神經(jīng)科學(xué)、表觀遺傳學(xué)和核信號(hào)傳導(dǎo)、信號(hào)轉(zhuǎn)導(dǎo)等眾多領(lǐng)域。為了更好地幫助客戶進(jìn)行科學(xué)研究，CUSABIO還成功生產(chǎn)了針對許多困難靶點(diǎn)的重組抗體，如：CLDN18.2、CLDN6、CCR8、SSTR2、DLL3、LY6G6D、ROR1、SEMA4D、GPC3、CD16A等。
產(chǎn)品優(yōu)勢
● 先進(jìn)的噬菌體展示技術(shù)
華美生物一直專注于將先進(jìn)的噬菌體展示技術(shù)應(yīng)用于廣泛的服務(wù)項(xiàng)目，特別是重組抗體的開發(fā)。
● 重組抗體種類繁多
華美生物可提供各種類型的重組抗體，包括全長抗體、scFv、Fab、sdAb、同種型/亞型和各種形式的 Fc 融合蛋白。
● 多種應(yīng)用類型可供選擇
華美生物的重組抗體已在多個(gè)應(yīng)用平臺(tái)驗(yàn)證，包括 WB、IF、IHC、FC、IP、ELISA、GICA 和 Neutralising。
Phospho-ERN1 (S724) Antibody (CSB-RA007795A724phHU)
Positive WB detected in: 293 whole cell lysate, A549 whole cell lysate, Hela whole cell lysate (treated with Calyculin A or EGF)
All lanes: Phospho-ERN1 antibody at 0.75μg/ml
Secondary
Goat polyclonal to rabbit IgG at 1/50000 dilution
Predicted band size: 110 kDa
Observed band size: 110 kDa
HSP90AA1/HSP90AB1 Antibody (CSB-RA010802A0HU)
Positive WB detected in: Hela whole cell lysate, MCF-7 whole cell lysate, K562 whole cell lysate, HL-60 whole cell lysate, HepG2 whole cell lysate, A549 whole cell lysate, Jurkat whole cell lysate, PC3 whole cell lysate, Rat brain tissue
All lanes: Hsp90 alpha + beta antibody at 1.25μg/ml
Secondary
Goat polyclonal to rabbit IgG at 1/50000 dilution
Predicted band size: 90 KDa
Observed band size: 90 KDa
GBA Antibody (CSB-RA869334A0HU)
Positive WB detected in: Hela whole cell lysate, MCF7 whole cell lysate, 293T whole cell lysate, U87 whole cell lysate, A549 whole cell lysate, Mouse Brain tissue, Rat Brain tissue
All lanes: GBA antibody at 1:500
Secondary
Goat polyclonal to rabbit IgG at 1/50000 dilution
Predicted band size: 60 kDa
Observed band size: 60 kDa
VDAC1 Antibody (CSB-RA025821A0HU)
Positive WB detected in: Hela whole cell lysate, HepG2 whole cell lysate, 293 whole cell lysate, Jurkat whole cell lysate, HL-60 whole cell lysate, LO2 whole cell lysate, Raji whole cell lysate, Rat heart tissue, Mouse brain tissue
All lanes: VDAC1 antibody at 0.7μg/ml
Secondary
Goat polyclonal to rabbit IgG at 1/50000 dilution
Predicted band size: 31 KDa
Observed band size: 31 KDa
Histone H3.3 Antibody (CSB-RA010109A0HU)
Immunofluorescence staining of Hela cells with the antibody at 1:60, counter-stained with DAPI.
CD21 Antibody (CSB-RA005934A0HU)
Immunofluorescence staining of Raji cells with the antibody at 1:34, counter-stained with DAPI.
Histone H3.1 Antibody (CSB-RA010418A0HU)
Immunofluorescence staining of Hela cells with the antibody at 1:93, counter-stained with DAPI.
CD97 Antibody (CSB-RA004972A0HU)
Immunofluorescence staining of Hela cells with the antibody at 1:87.5, counter-stained with DAPI.
CD34 Antibody (CSB-RA004926A0HU)
IHC image of the antibody diluted at 1:100 and staining in paraffin-embedded human kidney tissue performed on a Leica BondTM system.
CD4 Antibody (CSB-RA004935A0HU)
IHC image of the antibody diluted at 1:100 and staining in paraffin-embedded human spleen tissue performed on a Leica BondTM system.
CD44 Antibody (CSB-RA004938A0HU)
IHC image of the antibody diluted at 1:100 and staining in paraffin-embedded human tonsil tissue performed on a Leica BondTM system.
CD21 Antibody (CSB-RA005934A0HU)
IHC image of the antibody diluted at 1:100 and staining in paraffin-embedded human lung cancer performed on a Leica BondTM system.
CD81 Antibody (CSB-RA004960A0HU)
Overlay histogram showing Jurkat cells stained with the antibody (red line) at 1:50. Control antibody (green line) was used under the same conditions. Acquisition of >10,000 events was performed.
CD99 Antibody (CSB-RA004973A0HU)
Overlay histogram showing Jurkat cells stained with the antibody (red line) at 1:50. Control antibody (green line) was used under the same conditions. Acquisition of >10,000 events was performed.
CD74 Antibody (CSB-RA004956A0HU)
Overlay histogram showing Raji cells stained with the antibody (red line) at 1:50. Control antibody (green line) was used under the same conditions. Acquisition of >10,000 events was performed.
CD163 Antibody (CSB-RA801238A0HU)
Overlay histogram showing Raw264.7 cells stained with the antibody (red line) at 1:50. Control antibody (green line) was used under the same conditions. Acquisition of >10,000 events was performed.
Phospho-CDK2 (Y15) Antibody (CSB-RA005061A15phHU)
Positive WB detected in:Hela whole cell lysate, 293 whole cell lysate(treated with Pervanadate or not)
All lanes: Phospho-CDK2 antibody at 0.8μg/ml
Secondary
Goat polyclonal to rabbit IgG at 1/50000 dilution
Predicted band size: 34 KDa
Observed band size: 34 KDa
MAP2K1 Antibody (CSB-RA957619A0HU)
Positive WB detected in: Hela whole cell lysate, 293 whole cell lysate, MCF-7 whole cell lysate, 293T whole cell lysate, A549 whole cell lysate, U251 whole cell lysate, Rat brain tissue
All lanes: MAP2K1 antibody at 1:2000
Secondary
Goat polyclonal to rabbit IgG at 1/50000 dilution
Predicted band size: 44, 41 kDa
Observed band size: 44 kDa
PAK2 Antibody (CSB-RA592787A0HU)
Positive WB detected in: 293 whole cell lysate, Jurkat whole cell lysate, Raji whole cell lysate, Mouse brain tissue, Rat brain tissue
All lanes: PAK2 antibody at 1:2000
Secondary
Goat polyclonal to rabbit IgG at 1/50000 dilution
Predicted band size: 59 KDa
Observed band size: 59 KDa
PKM Antibody (CSB-RA632595A0HU)
Positive WB detected in: SH-SY5Y whole cell lysate, Jurkat whole cell lysate, MCF-7 whole cell lysate, Hela whole cell lysate, Raji whole cell lysate, 293 whole cell lysate, Mouse brain tissue
All lanes: PKM antibody at 1:2000
Secondary
Goat polyclonal to rabbit IgG at 1/50000 dilution
Predicted band size: 58, 59, 57 kDa
Observed band size: 58 kDa
Immobilize various types of SARS proteins at concentration of 2μg/ml on solid substrate, then react with SARS-CoV-2-S Antibody at concentration of 100μg/ml, 10μg/ml and 1μg/ml. It shows the SARS-CoV-2-S Antibody (CSB-RA33245A0GMY) is specific for SARS-CoV-2-S1-RBD protein, without any cross-reactivity with HCoV-OC43, HCoV-229E.
Immobilize various types of SARS proteins at concentration of 2μg/ml on solid substrate, then react with SARS-CoV-2-N Antibody at concentration of 100μg/ml, 10μg/ml and 1μg/ml. It shows the SARS-CoV-2-N Antibody (CSB-RA33255A0GMY) is specific for SARS-CoV-2-N protein, without any cross-reactivity with NL63-CoV, HCoV-OC43, HCoV-229E or HCoV-HKU1.
In the Colloidal Gold Immunochromatography Assay detection system, the background of antibody (CSB-RA33255A1GMY) is clean, the detection limit can be as low as 125ng/mL (8.75ng/0.07mL), and the sensitivity is very good.
In the Colloidal Gold Immunochromatography Assay detection system, the background of antibody (CSB-RA33255A2GMY) is clean, the detection limit can be as low as 15.625ng/ml (1.09ng/0.07ml), and the sensitivity is very good
Binding signal of SARS-CoV-2-S1-RBD (CSB-YP3324GMY1) and ACE2 protein-HRP conjugate (CSB-MP866317HU) was inhibited by S Antibody (CSB-RA33245A1GMY) with the IC50 is 2.38 μg/Ml.
SARS-CoV-2 Spike RBD Nanobody (CSB-RA33245A2GMY)
This nanobody competitively prevented SARS-CoV-2-S1-RBD (CSB-YP3324GMY1) from binding to ACE2-HRP conjugate (CSB-MP866317HU). The inhibition efficacy of the SARS-CoV-2-S1-RBD/ACE2 binding was positively proportionally to the nanobody concentrations. It showed that the nanobody effectively inhibited the SARS-CoV-2-S1-RBD/ACE2 binding. And the IC50 of the nanobody is 0.1074 μg/mL.
● 批間差異小
● 可持續(xù)性供應(yīng)
產(chǎn)品列表
您可以在下述列表中尋找您所需要的產(chǎn)品，或直接在頂部搜索框中輸入您需要查找的靶點(diǎn)、產(chǎn)品名稱、貨號(hào)。有任何問題，請點(diǎn)擊此處在線咨詢。
關(guān)于重組抗體
與傳統(tǒng)抗體相比，重組抗體的優(yōu)勢具體如下：
- 更高的一致性和重復(fù)性
因?yàn)橹亟M抗體是由一組獨(dú)特的基因發(fā)展而來的，所以抗體生產(chǎn)是可控且可靠的?？梢员苊怆s交瘤細(xì)胞制備中的一些問題，如基因丟失、基因突變和細(xì)胞株漂移等。這使得抗體的批次間差異非常小，從而為您提供高度可重復(fù)的結(jié)果。
- 更高的靈敏度和特異性
利用重組技術(shù)，更容易通過抗體工程提高抗體特異性和靈敏度。所需克隆的選擇過程發(fā)生在雜交瘤細(xì)胞和重組克隆階段，這使我們能夠選擇最優(yōu)的抗體質(zhì)量。
- 易于擴(kuò)展
隨著抗體基因的分離，與傳統(tǒng)單克隆技術(shù)相比，抗體表達(dá)能夠以任何規(guī)模在更短的時(shí)間內(nèi)進(jìn)行。這意味著我們可以在數(shù)周而非數(shù)月內(nèi)產(chǎn)生定制抗體。
- 無動(dòng)物高通量生產(chǎn)
一旦分離出產(chǎn)生抗體的基因，就可以實(shí)現(xiàn)無動(dòng)物體外生產(chǎn)。
重組抗體與傳統(tǒng)抗體的比較:
| 單克隆抗體 | 多克隆抗體 | 重組抗體 | |
|---|---|---|---|
| 重復(fù)性 | 高；批次間差異小 | 低 | 更高；高純度，批次間差異更小 |
| 特異性 | 強(qiáng) | 弱 | 更強(qiáng) |
| 生產(chǎn)周期 | 4到6個(gè)月的開發(fā)；4到6周的生產(chǎn) | 2到3個(gè)月的開發(fā)和生產(chǎn) | 4個(gè)月的開發(fā)；1到6周的生產(chǎn) |
| 同型亞基轉(zhuǎn)換 | 困難 | 困難 | 方便 |
| 表達(dá)系統(tǒng) | 小鼠腹水法和體外方法 | 通常在哺乳動(dòng)物細(xì)胞（如兔） | 通常在哺乳動(dòng)物細(xì)胞系中，也可在特殊工程細(xì)胞系中表達(dá)，如酵母、細(xì)菌、昆蟲和轉(zhuǎn)基因植物 |
| 成本 | 生產(chǎn)成本較高；需要更專業(yè)的人員操作 | 成本相對較低 | 需要技術(shù)專長和較大的時(shí)間和金錢投入進(jìn)行生產(chǎn) |
| 人類免疫應(yīng)答 | 無法避免 | 無法避免 | 可避免 |
引用文獻(xiàn)
S Antibody referenced in "A magneto-optical biochip for rapid assay based on the Cotton–Mouton effect of γ-Fe2O3@ Au core/shell nanoparticles", Journal of nanobiotechnology, 2021.
SARS-CoV-2 Spike RBD Nanobody referenced in "Potent antiviral activity of Agrimonia pilosa, Galla rhois, and their components against SARS-CoV-2", Bioorganic & Medicinal Chemistry, 2021.
HIF1A Antibody, CASP3 Antibody referenced in "PESV represses non-small cell lung cancer cell malignancy through circ_0016760 under hypoxia", Cancer cell international, 2021.
Phospho-ERN1 (S724) Antibody referenced in "The ER stress sensor inositol-requiring enzyme 1α in Kupffer cells promotes hepatic ischemia-reperfusion injury", Journal of Biological Chemistry, 2021.
CDK4 Antibody and CDK6 Antibody referenced in "Histone Deacetylase Inhibitor-Induced CDKN2B and CDKN2D Contribute to G2/M Cell Cycle Arrest Incurred by Oxidative Stress in Hepatocellular Carcinoma Cells Via Forkhead Box M1 Suppression", Journal of Cancer, 2021.
BIRC5 Antibody referenced in "LTBP4 Inhibits the Proliferation and Metastasis in Melanoma by Activating Hippo-YAP Signaling", Research Square, 2020.
